Randomized, double-blind trial of exifone versus cognitive problems in Parkinson's disease.

Abstract

Exifone is a novel substance of the benzophenone group that possesses potent scavenging properties. Initial findings demonstrate beneficial effects on age-related cognitive disorders. In this double-blind clinical trial versus placebo, the efficacy of 2 dosages (600 and 1200 mg/d) was evaluated with regard to Parkinson's disease (PD)-related cognitive disorders, for which there is increasing suspicion of a free-radicals origin. Despite disparities between the treatment groups as assessed by validated scales and subtests, and a considerable placebo effect on main parameters, both dose levels of exifone produced statistically significant improvement of the cognitive items most commonly impaired by PD: immediate recall, naming of objects presented, spatiotemporal orientation, and calculation. These properties suggest a new slot for exifone in the range of therapeutics available.

• Authors: H Allain, J Denmat, D Bentue-Ferrer, D Milon, P Pignol, J M Reymann, D Pape, O Sabouraud, J Van den Driessche
• Journal: Fundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 2 Issue 1 Pg. 1-12 ( 1988) ISSN: 0767-3981 [Print] England
• PMID: 3286439 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Benzophenones
• Psychotropic Drugs
• exifone

Topics

• Aged
• Benzophenones (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Cognition Disorders (drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Memory, Short-Term (drug effects)
• Middle Aged
• Parkinson Disease (drug therapy)
• Psychotropic Drugs (therapeutic use)
• Random Allocation